» Articles » PMID: 22096643

Hyperacute Corticosteroid Treatment of Optic Neuritis at the Onset of Pain May Prevent Visual Loss: a Case Series

Overview
Journal Mult Scler Int
Publisher Wiley
Date 2011 Nov 19
PMID 22096643
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Aim. To show that high-dose corticosteroids may prevent visual loss in patients with optic neuritis (ON) treated at the prodromal, hyperacute, phase of retrobulbar pain. Method. Prospective case series: patients were recruited with a history of ON associated with pain. The patients were advised to report immediately to the investigators should the pain recur in either eye. Where possible, orbital magnetic resonance imaging (MRI) was performed to confirm a recurrence of ON and treatment with high-dose corticosteroids was commenced. Visual function and the patient's subjective account were monitored. Results. Eight patients (including cases of MS, CRION and NMO) presented in the hyperacute phase. MRI confirmed optic nerve inflammation in 5/5. Treatment was commenced immediately, and, in all cases, no visual loss ensued. Conclusion. MRI can be used to confirm acute optic neuritis prior to visual loss in the hyperacute phase. We suggest that treatment with high-dose corticosteroids may abort the attack and prevent loss of vision in patients with ON who are treated at the onset of pain. This has potential implications for the management of acute ON and also for our understanding of the pathogenesis and potential therapeutic targets in the neuroinflammatory conditions associated with ON.

Citing Articles

Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?.

Buonfiglio F, Bohm E, Pfeiffer N, Gericke A Antioxidants (Basel). 2023; 12(7).

PMID: 37508003 PMC: 10376185. DOI: 10.3390/antiox12071465.


The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis.

Asseyer S, Asgari N, Bennett J, Bialer O, Blanco Y, Bosello F Front Neurol. 2023; 14:1102353.

PMID: 36908609 PMC: 9998999. DOI: 10.3389/fneur.2023.1102353.


Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis.

Ross A, Chaqour B, McDougald D, Dine K, Duong T, Shindler R Biomolecules. 2022; 12(6).

PMID: 35740955 PMC: 9221096. DOI: 10.3390/biom12060830.


Update on Optic Neuritis: An International View.

Hickman S, Petzold A Neuroophthalmology. 2022; 46(1):1-18.

PMID: 35095131 PMC: 8794242. DOI: 10.1080/01658107.2021.1964541.


Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.

Albert C, Mikolajczak J, Liekfeld A, Piper S, Scheel M, Zimmermann H BMC Neurol. 2020; 20(1):75.

PMID: 32126977 PMC: 7052969. DOI: 10.1186/s12883-020-01645-z.


References
1.
Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker B, Plant G . Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2009; 81(1):109-11. DOI: 10.1136/jnnp.2008.146894. View

2.
. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991; 109(12):1673-8. DOI: 10.1001/archopht.1991.01080120057025. View

3.
Fazzone H, Lefton D, Kupersmith M . Optic neuritis: correlation of pain and magnetic resonance imaging. Ophthalmology. 2003; 110(8):1646-9. DOI: 10.1016/S0161-6420(03)00477-9. View

4.
Lennon V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364(9451):2106-12. DOI: 10.1016/S0140-6736(04)17551-X. View

5.
Kapoor R, Miller D, Jones S, Plant G, Brusa A, Gass A . Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology. 1998; 50(1):230-7. DOI: 10.1212/wnl.50.1.230. View